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Down-regulation of human osteoblast PTH/PTHrP receptor alterations in mineral metabolism generated by renal
mRNA in end-stage renal failure. failure have profound effects on the skeleton. Abnormal-
Background. Resistance to the action of parathyroid hor- ities of bone turnover are characteristic of renal osteo-mone (PTH) has been demonstrated in end-stage renal failure
dystrophy. High turnover bone disease is typified by highand is considered to be important in the pathogenesis of sec-
numbers of osteoblasts and osteoclasts with high boneondary hyperparathyroidism. The mechanism of resistance is
unknown. However, altered regulation of cellular PTH/PTH- formation rates. Patients typically have elevated levels
related protein (PTH/PTHrP) receptor (PTH1R) has been as- of serum parathyroid hormone (PTH). In contrast, ab-
sumed to be important. normally low numbers of osteoblasts and osteoclasts areMethods. We have used in situ hybridization to examine
found in low turnover bone lesions (adynamic and osteo-PTH1R mRNA expression by osteoblasts in human bone and
malacia) with low bone formation rates and PTH levelshave compared the expression in high- and low-turnover renal
bone disease, high-turnover nonrenal bone disease (healing within or just above the normal range. PTH levels are
fracture callus and Pagetic bone), and normal bone. Bone usually elevated in end-stage renal disease as a probable
biopsies were formalin fixed, ethylenediaminetetraacetic acid consequence of decreased 1,25-dihydroxyvitamin D3, hy-decalcified, and paraffin wax embedded. A 1.8 kb PTH1R
perphosphatemia, hypocalcemia, and end-organ resis-cDNA probe, labeled with 35S, was used, and the hybridization
tance to PTH. Resistance to the action of PTH in patientssignal was revealed by autoradiography. The density of signal
over osteoblasts was quantitated using a semiautomated Lei- with chronic renal failure has been known for many
cae image analysis software package. years [1, 2]. These findings have been confirmed by the
Results. The mean density of PTH1R mRNA signal over
demonstration of a diminished calcemic response to PTHosteoblasts in renal high-turnover bone was only 36% of that
stimulation in both uremic dogs [3] and rats [4], whilefound in nonrenal high-turnover bone (P , 0.05) and 51% of
that found in normal bone (P , 0.05). Osteoblast PTH1R isolated perfused bones of uremic dogs have a blunted
mRNA signal in adynamic bone from individuals with diabetes cAMP response to PTH [5]. Furthermore, recent histo-
mellitus was 28% of normal bone (P , 0.05) and 54% of that morphometric studies of human bone biopsies have
found in renal high-turnover bone (P , 0.05).
shown that serum intact PTH (iPTH) levels several timesConclusions. These results demonstrate a down-regulation
greater than normal are required to maintain parametersof osteoblast PTH1R mRNA in end-stage renal failure in com-
parison to normal and high-turnover bone from otherwise of bone turnover within the normal range [6–11]. Such
healthy individuals, and provide an insight into the mechanisms data have led several authors to conclude that there
of “skeletal resistance” to the actions of PTH. must be altered regulation of PTH receptors, resulting
in “down-regulation” or “desensitization” [7, 12]. The
etiology of skeletal resistance to PTH in renal failure
Bone is influenced by the cumulative, long-term effects is unknown. Hyperphosphatemia [12, 13], deficiency of
of metabolic derangement, and thus, the long-standing vitamin D3 [14–19], uremic toxins (abstract; Dunlay et
al, Kidney Int 35:426, 1989) [4, 19], hypercalcitoninemia
[20], and hyperparathyroidism (abstract; ibid) [3, 19, 21]Key words: bone metabolism, kidney failure, renal osteodystrophy,
high turnover bone disease, parathyroid hormone receptor. have all been postulated as factors that modulate PTH
receptor function in vivo causing skeletal resistance inReceived for publication March 17, 1999
renal failure.and in revised form April 4, 2000
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related protein (PTHrP), the PTH/PTHrP receptor viduals obtained from the iliac crest at the time of bone
grafting (N 5 5).(PTH1R) [22]. Receptor regulation may occur at several
points, namely transcription, translation, receptor ex-
Sources and preparation of bone tissuepression, ligand affinity, and second-messenger/effector
Specimens examined were as follows: 13 illiac boneactivation [23]. With the cloning of the rat PTH1R
biopsies from individuals with ESRF, which showed no[24, 25], attention has focused on transcriptional regula-
evidence of a mineralization defect or aluminum deposi-tion of the receptor in renal failure in rats. Urena et al
tion; 2 illiac bone biopsies from patients with Paget’sisolated total RNA from bone and kidney of uremic rats
disease; 2 healing fracture callus specimens; and 5 sam-and found a decrease in PTHR1 mRNA compared with
ples of normal iliac bone. Bone trephines were split longi-normal rats [26]. Other authors have also recently re-
tudinally into two portions. One portion was fixed inported a down-regulation of PTH1R mRNA in kidney,
ethanol and embedded in methylmethacrylate resin.liver, and heart from uremic rats [27–29]. Although histo-
From these resin blocks, 7 m sections were cut using amorphometric data suggest that human bone cells exhibit
LKB macrotome, stained free-floating in toluidine blue,PTH resistance in renal failure [6–10], there is no expla-
and mounted on glass slides. All renal patients receivednation for this at the cellular level in vivo. Cloning of
1 g of oral tetracycline 14 and 4 days prior to bone biopsy.the human PTH1R gene [24, 25] and the development
For these samples, additional 15 mm sections were cutof molecular techniques such as in situ hybridization
for examination of tetracycline labeling using ultraviolet(ISH) have made it possible to address questions that
epi-illumination microscopy. The criteria for classifica-are fundamental in understanding renal bone cell biology
tion as either adynamic or high-turnover bone diseasein vivo. Therefore, the aim of this study was to investi-
have been published previously [30]. The second portiongate, using ISH, whether there is down-regulation of the
was fixed for 24 hours in 10% (vol/vol) neutral-bufferedPTH1R mRNA in human osteoblasts in renal failure as
formalin and then decalcified in 20% wt/vol ethylenedi-compared with normal osteoblasts and osteoblasts in
aminetetraacetic acid (EDTA; pH 7.2) until radiologi-other high-turnover bone states.
cally decalcified (10 to 14 days). Following decalcifica-
tion, the tissue was processed routinely into paraffin wax
METHODS and 5 mm sections mounted onto silanated slides [31]
for ISH.Subjects
This study comprised 13 individuals with renal failure In situ hybridization
(8 male and 5 female, mean age of 46.1 years, range 27 Probe. A human cDNA probe (1.8 kb) to PTH1R (a
to 63 years). Of these, three individuals were in end- generous gift from Dr. Schipani, Boston, MA, USA) was
stage renal failure (ESRF) and had a trans-iliac bone random prime labeled to a specific activity of approxi-
biopsy under general anesthetic at the time of Tenckhoff mately 1 3 108 cpm/g using 35S dCTP. For control pur-
catheter insertion; the remaining 10 individuals were re- poses, similarly sized fragments of lambda DNA labeled
ceiving continuous ambulatory peritoneal dialysis (mean to the same specific activity were used.
duration of 25.5 months, range 1 to 48 months). The Hybridization. The prehybridization treatments were
cause of renal failure in two individuals was unknown. as detailed previously [32]. Briefly, these included se-
Two had autosomal dominant polycystic kidney disease. quential immersion in 0.2N HCl (20 min), 0.2 3 standard
Two individuals were recorded as having hypertensive saline citrate (SSC 5 0.15 mol/L NaCl and 0.015 mol/L
renal disease. One had chronic pyelonephritis, and six sodium citrate, 10 min); g/mL of proteinase K in 50
had diabetic nephropathy. All subjects were taking cal- mmol/L Tris-HCl, pH 7.5, one hour at 378C; 0.2% (wt/
cium carbonate with meals as a phosphate binder, and vol) glycine in phosphate-buffered saline (PBS); and
none were taking aluminum-containing phosphate bind- 0.4% (wt/vol) paraformaldehyde in PBS, pH 7.0 (20
ers. No subject had been treated with vitamin D or had min), and freshly prepared 0.25% (vol/vol) acetic anhy-
undergone parathyroidectomy. None of the females had dride in 0.1 mol/L triethanolamine, pH 8. Following pro-
received hormone replacement therapy. Blood sampling teinase treatment, serial sections were reacted with 1
was carried out on the same day as bone biopsy to allow mg/mL of RNAse A in 0.5 3 SSC for one hour at 378C.
measurement of ionized calcium, serum phosphate, se- All sections were prehybridized for one hour at 378C in
rum iPTH, and serum 1,25(OH)2D3. The study also com- 50% formamide, 1 mg/mL of bovine serum albumin,
prised individuals with normal renal function with Pag- 0.02% (wt/vol) Ficoll, 0.02% (wt/vol) polyvinyl pyrroli-
et’s disease (N 5 2, both male, 61 and 58 years old) and done, 0.6 mol/L NaCl, 0.2 mg/mL of sheared salmon
healing bone fracture (N 5 2, both male, 42 and 47 years sperm DNA, 10 mmol/L Tris (pH 7.4), 0.5 mmol/L
old), which comprised the nonrenal high-turnover group EDTA, 10 mmol/L dithiothreitol (DTT), and 10% (wt/
vol) dextran sulfate. Hybridization with heat denaturedand specimens of normal bone from age-matched indi-
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35S-labeled probe (100 ng/mL prehybridization solution) groups, and data are represented as the mean and 95%
CI. Comparisons between histologic groups were carriedwas carried out at 378C overnight. After hybridization,
the tissue sections were washed with a series of high- out using the Mann–Whitney U-test. Differences were
considered significant at a value of P , 0.05. In the renalstringency washes: twice for 5 minutes in 0.5 3 SSC
with 1 mmol/L EDTA and 10 mmol/L DTT; twice for high- and low-turnover groups, Spearman’s rank-order
correlation was used to investigate the relationship be-5 minutes in 0.5 3 SSC with 1 mmol/L EDTA; 15 minutes
in 50% formamide, 0.15 mol/L NaCl, 5 mmol/L Tris (pH tween serum iPTH, serum phosphate, ionized calcium,
serum 1,25(OH)2D3, duration of dialysis, and the age of7.5), and 0.5 mmol/L EDTA; four times for 5 minutes
in 0.5 3 SSC at 558C, followed by 5 minutes at room subject at the time of bone biopsy and PTH1R mRNA
signal.temperature in 0.5 3 SSC. Slides were then dehydrated
in 70 and 90% ethanol with 0.3 mol/L ammonium acetate
and were air dried. Autoradiography was performed with
RESULTS
Ilford K5 emulsion melted at 408C and was diluted 1:1
Biochemistrywith distilled water. The slides were exposed at 48C for
14 days and then developed in Kodak D 19 developer The mean serum iPTH for the group with hyperpara-
thyroid bone disease (N 5 9) was 644 pg/mL (range 180for five minutes, rinsed, fixed for five minutes, and coun-
terstained with hematoxylin and eosin. to 1700 pg/mL) and 85 pg/mL (range 30 to 148 pg/mL)
for those with diabetes and adynamic bone (N 5 4). TheQuantitation. Analysis of autoradiographic signal over
bone cells was performed using a Quantimete semiauto- normal range for serum iPTH was 10 to 65 pg/mL. The
mean serum 1,25(OH)2D3 for the hyperparathyroid bonemated image analysis system incorporating software de-
signed in conjunction with Leica Software Systems (Mil- group was 7.8 pg/mL (range 0 to 18 pg/mL) and 5.8
pg/mL (range 3 to 10 pg/mL) for the group with adynamicton Keynes, UK). Analysis was performed by two
investigators (P.M. and J.A.H.). Using t-test and analysis bone and diabetes mellitus. Levels of 1,25(OH)2D3
greater then 20 pg/mL are considered normal. The meanof variance (ANOVA), there was no significant differ-
ence between the two observers (P , 0.05). ISH was serum phosphate for the hyperparathyroid bone group
was 2.1 mmol/L (range 1.2 to 3.07 mmol/L), and thatperformed four times on a series of biopsies, and no
significant difference was found between ISH runs (P , for the diabetic-adynamic bone group was 1.7 mmol/L
(range 1.54 to 2.16). The normal range was 0.75 to 1.50.05). Signal density (grains per unit area of cell) was
analyzed for osteoblasts. For each biopsy, approximately mmol/L. Mean ionized calcium for the hyperparathyroid
bone group was 1.24 mmol/L (range 1.01 to 1.41 mmol/L)10 random high-power fields were examined or as many
as possible if less than 10. All osteoblasts within each and for the diabetic-adynamic bone group was 1.2
mmol/L (range 1.12 to 1.22 mmol/L). The normal rangehigh-power field were identified and their area and that
portion of that area covered by signal measured in arbi- is taken as 1.12 to 1.33 mmol/L. The complete biochemi-
cal data are shown in Table 1.trary pixel units. This represents “Signal Density.” Back-
ground signal over matrix and noncellular areas of bone
Cellular localization of PTHR1 mRNAwas measured in two random high-power fields in the
same manner. Results were recorded as the mean density PTH1R mRNA hybridization signal was generally
greatest over osteoblasts with variation in signal intensityof signal over cells in all fields, minus the background
signal. seen in the different bone states studied (Fig. 1). In
addition, in individual biopsies, some variability in inten-Biochemistry. Serum iPTH levels were measured in
all renal patients using a commercially available two-site sity of signal was apparent with “plump” osteoblasts in
areas of active matrix synthesis most positive. There wasimmunoradiometric assay (IRMA) for the measurement
of PTH (Nichols Institute Diagnostics, San Juan Capis- no difference between cortical and trabecular osteo-
blasts. No signal was seen over flat resting surface cells,trano, CA, USA). Serum levels of 1,25(OH)2D3 were
measured using a method previously described [33]. Se- and osteocytes were not convincingly positive except in
healing fracture callus. This pattern of signal expressionrum phosphate was measured by colorimetric assay using
a Hitachi 747 Autoanalyzer (Nissei Sangyo Co., Ltd., was seen in all bone studied, although the level of signal
differed. Flat elongated fibroblast-like cells in areas ofLondon). Ionized calcium was determined using a Radi-
ometer ICA2 electrode. peritrabecular fibrosis (in the renal bone biopsies) were
positive, although much less than osteoblasts. This was
Statistical analysis particularly the case when peritrabecular fibrosis was
adjacent to trabecular surfaces, which were being ac-Summary statistics in the form of means and 95%
confidence intervals (95% CI) were calculated for tively remodeled. Scattered unidentifiable bone marrow
cells were positive. Clearly, the localized hybridizationmRNA signal density for normal bone, Paget’s disease
and healing fracture, and renal high- and low-turnover signal was also seen over actively resorbing osteoclasts
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Table 1. Biochemical and clinical data for ESRF subjects with high-turnover bone disease (H1–9) and adynamic bone disease (A1–4)
Dialysis Serum PTH1R
Age duration Histological iPTH iCa 1,25(OH)2D3 phosphate mRNA
Patient Gender years Renal disease Months diagnosis pg/mL mmol/L pg/mL mmol/L signal
H1 Male 27 Chronic pyelonephritis 25 HPT 1700 1.2 0 3.07 4.85
H2 Female 63 Unknown 1 HPT 305 1.19 7 1.2 2.99
H3 Male 63 Hypertensive renal disease 48 HPT 740 1.41 9 2.05 4.47
H4 Female 45 APKD 24 HPT 570 1.18 4 1.73 2.33
H5 Male 50 Diabetic nephropathy 0 HPT 180 1.15 4 1.29 4.46
H6 Male 40 Diabetic nephropathy 0 HPT 185 1.22 8 1.81 3.11
H7 Male 30 APKD 0 HPT 195 1.27 14 1.74 5.83
H8 Female 35 Unknown 36 HPT 580 1.24 18 2.64 3.33
H9 Female 51 Hypertensive renal disease 7 HPT 1340 1.26 6 2.99 3.38
A1 Male 57 Diabetic nephropathy 16 ABD 38 1.12 3 2.16 1.48
A2 Male 55 Diabetic nephropathy 40 ABD 148 1.17 3 1.65 1.67
A3 Female 46 Diabetic nephropathy 48 ABD 125 1.22 7 1.63 1.37
A4 Male 37 Diabetic nephropathy 32 ABD 30 1.18 10 1.54 3.2
in renal hyperparathyroid bone, healing fracture callus, bone from two uremic rats and found a PTH1R mRNA/
28S ratio of 0.78 in normal animals compared with 0.59and particularly in Pagetic bone (Fig. 2). In Pagetic bone,
in rats with chronic renal failure illustrating a down-the hybridization signal was often greater over osteo-
regulation of receptor mRNA in skeletal tissue [26]. Inclasts than over osteoblasts. No identifiable osteoclasts
this study of osteoblasts in human bone, the meanwere seen in normal bone.
PTH1R mRNA signal density in high-turnover renal os-
Quantitation of PTH1R mRNA expression teodystrophy samples was 3.70 (3.40 to 4.13, 95% CI)
and in diabetic-adynamic renal bone was 1.99 (1.27 toPTH1R mRNA expression in osteoblasts was signifi-
2.70, 95% CI). By contrast, in the nonrenal high-turnovercantly less in renal high-turnover bone (mean 3.70, 3.40
specimens, the mean signal density was 10.30 (9.72 toto 4.13, 95% CI) than either the fracture and Pagetic
10.87, 95% CI) and in normal bone was 7.24 (6.41 tobone (mean 10.30, 9.72 to 10.87, 95% CI) or normal
8.08, 95% CI). Hence, renal high-turnover osteoblastsbone (mean 7.24, 6.41 to 8.08, 95% CI, P , 0.05). In
in vivo had levels of PTH1R mRNA expression thatdiabetic-adynamic bone, PTH1R mRNA expression
were 36 and 51% of levels found in nonrenal high-turn-(mean 1.99, 1.27 to 2.70, 95% CI) was significantly less
over and normal bone, respectively. Osteoblasts fromthan in high-turnover renal bone and normal bone (P ,
diabetic-adynamic bone had receptor mRNA expression0.05; Fig. 3). There were no significant correlations be-
28% of normal osteoblasts and 54% of the expressiontween PTH1R mRNA signal and serum PTH (rs 5 0.58),
found in high-turnover renal bone. Our data show down-serum 1,25(OH)2D3 (rs 5 0.24), serum phosphate (rs 5
regulation of PTH1R mRNA in the PTH target tissue,0.34), ionized calcium (rs 5 0.50), age at time of biopsy
bone. The decrease in PTH1R expression at the level of(rs 5 20.38). or dialysis duration (rs 5 20.26) when
the osteoblast may represent the molecular basis for theanalyzed using Spearman’s rank-order correlation in the
resistance of the skeleton to PTH in uremic patients. It13 ESRF patients examined (Fig. 4).
must be noted that we have shown down-regulation of
receptor mRNA and not of the receptor protein itself,
DISCUSSION although it is probable that the expression of the receptor
Parathyroid hormone has a central role in renal osteo- protein is also down-regulated in uremia. However, this
dystrophy, and the cloning of the PTH1R gene has made still remains to be demonstrated.
it possible to investigate the possibility of altered recep- In a study of this nature, where the number of biop-
tor mRNA regulation. Although several authors have sies is small, it is difficult to draw definite conclusions
suggested that abnormal regulation of the PTH1R by about the roles of serum PTH, ionized calcium, serum
bone cells in patients with ESRF is likely to be important phosphate, serum vitamin D3, and uremic factors in the
in the pathogenesis of skeletal resistance to PTH found pathogenesis of PTH1R modulation, in particular the
in these patients [7, 11], to our knowledge, this is the down-regulation of receptor mRNA. There is general
first time that a reduction in steady-state levels of PTH1R agreement in the literature regarding the negative regu-
mRNA has been demonstrated in human osteoblasts. latory effect of PTH on PTH1R expression and cAMP
PTH1R mRNA in vivo has been shown to be down- production in vitro [34–41]. More recently, the expres-
regulated in uremic rat kidney [26, 27], liver [28], and sion of PTH1R receptor mRNA in vitro has been exam-
ined and found to be reduced in response to PTH stimu-heart [29]. Interestingly, Urena et al have also examined
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Fig. 1. Photomicrograph showing PTH1R mRNA expression [visualized as black (silver) autoradiographic grains] by osteoblasts (arrow) lining
the bone surface in (a and b) renal hyperparathyroid bone (a, magnification 350; b, magnification 3200), (c and d ) normal bone (magnification
3250), and (e and f ) normal healing fracture callus (e, magnification 350; f, magnification 3200). Note the increase in signal seen in nonuremic
osteoblasts compared with those in renal bone.
lation [42–46]. The data obtained from experimental parathyroidectomy in animals without renal failure did
not increase the expression of PTH1R mRNA [48]. Inanimals, however, have not been as clear cut. A reduction
of increased PTH levels to normal did not improve the our present study, the majority of individuals had serum
PTH levels that were elevated above normal, althoughblunted calcemic response to PTH in azotemic animals
(abstract; Bover et al, XIIth International Congress of those individuals with the higher levels were those with
high-turnover bone disease and had relatively higherNephrology, Jerusalem, Israel, June 13–18, 1993, p 453).
In addition, Urena et al have shown that thyroparathyro- levels of PTH1R mRNA expression. This would argue
against PTH being the cause of receptor mRNA down-idectomy does not prevent renal PTH1R mRNA down-
regulation in uremic rats, suggesting that hyperparathy- regulation.
The role of 1,25(OH)2D3 in vivo is to improve or abol-roidism is not essential for down-regulation to occur [47].
Others have found that selective parathyroidectomy did ish resistance to PTH in uremic individuals [14–18]. Stud-
ies in vitro reveal that the cAMP response of bone cellsnormalize receptor mRNA levels in uremic rat kidney,
liver, and heart [27–29]. This same group found that from vitamin D-deplete animals to PTH stimulation is
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Fig. 2. Photomicrograph showing PTH1R mRNA expression by osteoclasts in renal hyperparathyroid bone (a, magnification 3100) and Pagetic
bone (b, magnification 3100). Note the increase in hybridization signal in Pagetic osteoclasts.
Fig. 3. Levels of osteoblast PTH1R mRNA signal in different bone states. PTH1R mRNA hybridization signal in osteoblasts from fracture callus
(F1-2), Pagetic bone (P1-2), normal bone (N1-4), renal hyperparathyroid (H1-9), and diabetic-adynamic bone (A1-4). Mean signal density values
(per unit area of cell) with 95% CI are presented for each individual.
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Fig. 4. PTH serum levels, serum phosphate, ionized calcium, serum 1,25(OH)2D3 and age of subject at time of biopsy correlated with PTH1R
mRNA hybridization signal density (N 5 13 renal bone biopsies).
increased after treatment of those bone cells with vitamin Intracellular calcium levels have been felt to be impor-
tant in the down-regulation of PTH1R mRNA in ratD [49]. However, the majority of in vitro experiments
reveal a reduction in cAMP response [50] and a reduc- kidney, liver, and heart [28, 29, 48, 56]. However, in
this present study, we found no significant correlationtion in receptor number and receptor mRNA [51] after
treatment with 1,25(OH)2D3. It would seem that the level between extracellular ionized calcium and receptor
mRNA signal.of vitamin D depletion and the presence of uremia are
important factors in determining the effect of vitamin In the present study, the duration of peritoneal dialysis
was significantly different between the high- and low-D. No significant correlation was found between serum
1,25(OH)2D3 and receptor mRNA signal in the group of turnover bone groups, with the adynamic group being
on dialysis for longer (P , 0.05). Other studies haveindividuals examined in this study.
In vivo studies carried out in animals with renal failure indicated that continuous ambulatory peritoneal dialysis
is associated with adynamic bone disease [57], and inhave implicated hyperphosphatemia as an important fac-
tor in the development of PTH resistance [13, 52]. In our study, adynamic bone is associated with lower levels
of receptor mRNA. It must be noted that all of thoseaddition, in vitro experiments have shown that both high
[12, 53, 54] and low [55] extracellular levels of phosphate individuals with adynamic bone had diabetes mellitus,
which is itself associated with adynamic bone disease,reduce either cAMP or calcium efflux from bone in re-
sponse to PTH stimulation. No significant correlation and diabetes mellitus has also been shown to be associ-
ated with the down-regulation of the PTH1R mRNAwas found between serum phosphate and receptor
mRNA signal in the group of individuals examined in in renal tissue [56]. Thus, it remains unclear whether
duration of dialysis, the presence of diabetes mellitus,our study.
Picton et al: PTH1R mRNA regulation in uremia 1447
1,25 dihydroxyvitamin on skeletal resistance to parathyroid hor-or the low bone-turnover state per se is crucial in this
mone. Kidney Int 32:801–807, 1987
situation. 4. Bover J, Jara A, Trinidad P, Rodriguez M, Martin Malo A,
Felsenfeld AJ: The calcaemic response to PTH in the rat: EffectLocal factors in the bone environment are almost cer-
of elevated PTH levels and uraemia. Kidney Int 46:310–317, 1994tainly involved in the modulation of osteoblast PTH1R
5. Olgaard K, Schwartz J, Finco D, Arbelaez M, Korkor A,
expression. In vitro, tumor necrosis factor-a [58–61], in- Martin K, Klahr S, Slatopolsky E: Extraction of parathyroid
hormone and release of adenosine 3,5-monophosphate by isolatedterleukin-1 [58, 62], transforming growth factor-b [63–66],
perfused bones obtained from dogs with acute uremia. Endocrinol-epidermal growth factor [67], and PTHrP [68] have all
ogy 111:1678–1682, 1982
been shown to affect the expression or function of the 6. Cohen-Solal ME, Boudailliez B, Sebert JL, Westeel PF, Bouil-
lon R, Fournier A: Comparison of intact, mid region and carbox-PTHR1 in osteoblast-like cells. In addition, type I colla-
yterminal assays of parathyroid hormone for the diagnosis of bonegen and matrix proteins are known to influence receptor
disease in haemodialysed patients. J Clin Endocrinol Metab 73:516–
expression [69, 70]. The importance of these local factors 524, 1991
7. Quarles LD, Lobaugh B, Murphy G: Intact parathyroid hormoneis illustrated in the cases of Paget’s disease and fracture
overestimates the presence and severity of parathyroid mediatedhealing, situations in which systemic factors are generally
osseous abnormalities in uraemia. J Clin Endocrinol Metab 75:145–
unaltered through bone remodeling, and from this study 150, 1992
8. Sherrard DJ, Merez G, Pei Y, Maloney NA, Greenwood C,PTH1R mRNA expression is greatly increased. There-
Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum offore, alterations in the expression of these locally acting
bone disease in end-stage renal failure: An evolving disorder. Kid-
growth factors and cytokines in uremia may be important ney Int 43:436–442, 1993
9. Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcionin explaining the altered expression of PTH1R mRNA
MT, Rodriguez AP, Hernandez A, Debonis E, Darias E, Gonza-in renal failure.
lez-Posade JM, Losada M, Rufino M, Felsenfeld AJ, Rodri-
In contrast to many previous studies, but consistent guez M: Bone disease in predialysis, hemodialysis and CAPD
patients: Evidence for a better bone response to PTH. Kidney Intwith data by Tong et al (abstract; J Bone Miner Res
47:1434–1442, 199510:5278, 1995), who showed that isolated mouse osteo-
10. Qui Q, Monier-Faugere M, Geng Z, Malluche H: Predictive
clasts expressed PTH1R mRNA, human osteoclasts (in value of serum parathyroid levels for bone turnover in patients
with chronic maintenance dialysis. Am J Kidney Dis 26:622–631,high-turnover bone states) were positive for PTH1R
1995mRNA. This supports previous in vitro evidence that
11. Slatopolsky E, Delmez J: Pathogenesis of secondary hyperpara-
osteoclasts have the potential to respond to PTH directly thyroidism. Am J Kidney Dis 23:229–236, 1994
12. Somerville PJ, Kaye M: Action of phosphorus on calcium release[71–73]. In fracture callus and renal high-turnover bone
in isolated perfused rat tails. Kidney Int 22:348–354, 1982expression of receptor mRNA was less than or equal to
13. Rodriguez M, Martin-Malo A, Martinez ME, Torres A,
that of osteoblasts. However, in Pagetic osteoclasts the Felsenfeld AJ, Llach F: Calcaemic response to parathyroid hor-
mone in renal failure: Role of phosphorus and its effect on calcitriol.expression of receptor mRNA was higher than that by
Kidney Int 40:1055–1062, 1991osteoblasts and is consistent with the altered gene ex-
14. Somerville PJ, Kaye M: Resistance to parathyroid hormone in
pression previously reported [74–76] and may be impor- renal failure: Role of vitamin D metabolites. Kidney Int 14:245–254,
tant in maintaining the Pagetic phenotype. 1978
15. Massry S, Stein R, Garty J, Arieff A, Coburn J, Norman A,In conclusion, our data show that there is a reduction
Friedler R: Skeletal resistance to the calcaemic action of parathy-in steady-state levels of the PTH1R mRNA in human roid hormone in uremia: Role of 1,25 dihydroxyvitamin D. Kidney
osteoblasts in vivo in ESRF, and this may represent the Int 9:467–474, 1976
16. Massry S, Tuma S, Dua S, Goldstein D: Reversal of skeletalmolecular basis for the resistance of skeletal tissue to
resistance to parathyroid hormone in uremia by vitamin D metabo-PTH in uremic patients. lites. J Lab Clin Med 94:152–157, 1979
17. Jacob AI, Gavellas G, Canterbury J, Bourgoignie JJ: Calcemic
and phosphaturic response to parathyroid hormone in normal andACKNOWLEDGMENTS
chronically uremic dogs. Kidney Int 22:21–26, 1982
Funding for this study was provided in part by the Baxter Extramural 18. Wilson L, Felsenfeld A, Drezner MK, Llach F: Altered diva-
Grant Program and the National Kidney Association. We thank Dr. lent ion metabolism in early renal failure: Role of 1,25(OH)2D.
E. Schipani, Endocrine Unit, Harvard Medical School (Boston, MA, Kidney Int 27:565–573, 1985
USA), for the PTH1R cDNA probe and Mrs. Pauline Baird for excel- 19. Rodriguez M, Felsenfeld AJ, Llach F: Calcaemic response to
lent technical assistance. parathyroid hormone in renal failure. Role of calcitriol and the
effect of parathyroidectomy. Kidney Int 40:1063–1068, 1991
Reprint requests Judith A. Hoyland, Ph.D., Musculoskeletal Research 20. Rodriguez M, Felsenfeld AJ, Torres A, Pederson L, Llach
Group, School of Medicine, Stopford Building, University of Manches- F: Calcitonin, an important factor in the calcaemic response to
ter, Oxford Road, Manchester, England M13 9PT, United Kingdom. parathyroid hormone in the rat. Kidney Int 40:219–225, 1991
E-mail: JHoyland@FS1.SCG.MAN.AC.UK 21. Olgaard K, Arbelaez M, Schwartz J, Klahr S, Slatopolsky
E: Abnormal skeletal response to parathyroid hormone in dogs
with chronic uraemia. Calcif Tissue Int 34:403, 1982REFERENCES
22. Ju¨ppner H, Abou-Samra AB, Freeman MW, Long XF, Schipani
E, Richards J, Kolakowski LF Jr, Hock J, Potts JT Jr, Kro-1. Evanson JM: The response to the infusion of parathyroid extract
nenberg HM, Segre GV: A G protein linked receptor for parathy-in hypocalcaemic states. Clin Sci 31:63–78, 1966
roid hormone and parathyroid hormone related peptide. Science2. Massry SG, Coburn JW, Lee DBM, Towsey J, Kleeman C: Skele-
254:1024–1026, 1991tal resistance to parathyroid hormone in renal failure: Study in
23. Barnes P: Molecular biology of receptors. Q J Med 301:339–353,105 human subjects. Ann Intern Med 78:357–364, 1973
3. Galceran T, Martin KJ, Morrissey JJ, Slatopolsky E: Role of 1992
Picton et al: PTH1R mRNA regulation in uremia1448
24. Abou-Samra AB, Ju¨ppner H, Force T, Freeman MW, Kong XF, perifused human osteosarcoma cells (SaOS-2). Biochim Biophys
Schipani E, Ureria P, Richards J, Bonventre JV, Potts JTJ, Acta 1222:447–456, 1994
Kronenberg HM, Segre GV: Expression cloning of a common 42. Fukayama S, Schipani E, Juppner H, Lanske B, Kronenberg
receptor for parathyroid hormone and parathyroid hormone re- H, Abou-Samra A, Bringhurst F: Role of protein kinase-A in
lated peptide from rat osteoblast like cells: A single receptor stimu- homologous down-regulation of parathyroid hormone (PTH)/
lates intracellular accumulation of both cAMP and inositol triphos- PTH-related peptide messenger ribonucleic acid in human osteo-
phates and increases intracellular free calcium. Proc Natl Acad Sci blast-like SaOS-2 cells. Endocrinology 134:1851–1858, 1994
USA 89:2732–2736, 1992 43. Kitten A, Lee J, Olson M: Osteogenic protein-1 enhances pheno-
25. Schipani E, Karga H, Koraphis A, Potts JF Jr, Kronenberg HM, typic expression in ROS 17/2.8 cells. Am J Physiol 269:918–926,
Segre GV, Abou-Samra AB, Ju¨ppner H: Identical complementary 1995
deoxyribonucleic acids encode a human renal and bone parathy- 44. Urena P, Iida-Klein A, Kong XF, Abou-Samra AB, Segre GV:
roid hormone PTH/PTHrP peptide receptor. Endocrinology Regulation of the PTH/PTHrP receptor mRNA by glucocorticoids
132:2157–2165, 1993 and PTH in ROS 17/2.9 OK cells. Endocrinology 134:451–456,
26. Urena P, Kubrusly M, Mannstradt M, Hruby M, Tan MTT, 1994
Silve C, Lacour B, Abou-Samra A, Segre G, Dru¨eke T: The 45. Gonzalez E, Martin K: Coordinate regulation of PTH/PTHrP
renal PTH/PTHrP receptor is down-regulated in rats with chronic receptors by PTH and calcitriol in UMR 106-01 osteoblast-like
renal failure. Kidney Int 4S:605–611, 1994 cells. Kidney Int 50:63–70, 1996
27. Tian J, Smogorzewski M, Kede SL, Massry SG: PTH/PTHrP 46. Jongen J, Willemstein-Van Hove E, Van Der Meer J, Bos M,
receptor mRNA is down-regulated in chronic renal failure. Am J Juppner H, Segre G, Abou-Samra A, Feyen J, Herrmann-Erlee
Nephrol 14:41–46, 1995 M: Down regulation of the receptor for parathyroid hormone
28. Massry SG, Klin M, Ni Z, Tian J, Kedes L, Smogorzewski M: (PTH) and PTH-related peptide by transforming growth factor-b
Impaired agonist-induced calcium signalling in hepatocytes from in primary fetal rat osteoblasts. Endocrinology 136:3260–3266, 1995
chronic renal failure rats. Kidney Int 48:1324–1331, 1995 47. Urena P, Mannstadt M, Hruby M, Ferreira A, Schmitt F, Silve
29. Smogorzewski M, Tian J, Massry SG: Down regulation of PTH/ C, Ardaillou R, Lacour B, Abou-Samra A-B, Segre GV, Dru¨eke
PTHrP receptor of heart in CRF: Role of [Ca21]. Kidney Int T: Parathyroidectomy does not prevent the renal PTH/PTHrP
47:1182–1186, 1995 receptor down regulation in uraemic rats. Kidney Int 47:1797–1805,
30. Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, 1995
Mawer EB, Freemont AJ, Gokal R: Correlation of bone histology 48. Smogorzewski M, Marcinkowski W, Zhang G, Massry SG: Para-
with parathyroid hormone, vitamin D3 and radiology in end-stage thyroidectomy does not affect mRNA of PTH/PTHrP receptor in
renal disease. Kidney Int 44:1071–1077, 1993 kidney, liver, and heart. Am J Nephrol 17:187–192, 1997
31. Rentrop M, Knapp B, Winter M, Schwei¨zer J: Amino-lysilane 49. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C,
treated glass slide support for ISH of kerratin cDNAs to frozen Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of
sections under varying fixation and protreatment conditions. Histo- bone disease in end-stage renal failure: An evolving disorder. Kid-
chem J 18:271–276, 1986 ney Int 43:436–44232. Hoyland JA, Freemont AJ, Sharpe P: Interleukin 6, IL-6 receptor 50. Wong GL, Luben RA, Cohn DV: 1,25-Dihydroxycholecalciferoland 1L-6 nuclear factor gene expression in Paget’s disease. J Bone
and parathormone: Effects on isolated osteoclast-like and osteo-Miner Res 9:75–80, 1994
blast-like cells. Science 197:663–665, 197733. Mawer E, Berry J, Cundall J, Still P, White A: A sensitive
51. Titus L, Jackson E, Nanes MS, Rubin JE, Catherwood BD:radioimmunoassay that is equipotent for 1,25-dihydroxyvitamin
1,25-Dihydroxyvitamin D reduces parathyroid hormone receptorD2 and D3. Clin Chim Acta 190:199–210, 1990 number in ROS 17/2.8 cells and prevents the glucocorticoid-in-34. Herrmann-Erlee M, Van Der Meer J, Hekkelman J: In vitro
duced increase in these receptors: Relationship to adenylate cyclasestudies of the adenosine 39,59-monophosphate (cAMP) response
activation. J Bone Miner Res 6:631–637, 1991of embryonic rat calvaria to bovine parathyroid hormone-(1-84)
52. Somerville PJ, Kaye M: Evidence that resistance to the calcaemic[bPTH-(1-84)], bPTH-(1-34) and bPTH-(3-34) and the loss of
action of parathyroid hormone in rats with acute uremia is causedcAMP responsiveness after prolonged incubation. Endocrinology
by phosphate retention. Kidney Int 16:552–560, 1979106:2013–2018, 1980
53. Raisz LG, Niemann I: Effect of phosphate, calcium and magne-35. Kent G, Jilka R, Cohn D: Homologous and heterologous control
sium on bone resorption and hormonal responses in tissue culture.of bone cell 39,59-monophosphate response to hormones by PTH,
Endocrinology 85:446–452, 1969prostaglandin E2, calcitonin and 1,25-dihydroxycholecalciferol.
54. Wills MR, Jenkins MV: The effect of uraemic metabolites onEndocrinology 107:1474–1481, 1980
parathyroid extract-induced bone resorption in vitro. Clin Chim36. Teitelbaum A, Silve C, Nyiredy K, Arnaud C: Down-regulation
Acta 73:121–125, 1976of parathyroid hormone (PTH) receptors in cultured bone cells is
55. Marcinkowski W, Smogorzewski M, Zhang G, Ni Z, Kedes L,associated with agonist-specific intracellular processing of PTH-
Massry SG: Renal mRNA of PTH-PTHrP receptor, [Ca21]i andreceptor complexes. Endocrinology 118:595–602, 1986
phosphaturic response to PTH in phosphate depletion. Miner Elec-37. Yamamoto I, Shigeno C, Potts J, Segre G: Characterization and
trolyte Metab 23:48–57, 1997agonist-induced down-regulation of parathyroid hormone recep-
56. Marcinkowski W, Zhang G, Smogorzewski M, Massry SG: Ele-tors in clonal rat osteosarcoma cells. Endocrinology 122:1208–1217,
vation of [Ca21] of renal proximal tubular cells and down-regula-1988
tion of mRNA of PTH-PTHrP, V1a and AT1 receptors in kidney38. Mitchell J, Goltzman D: Mechanisms of homologous and heter-
of diabetic rats. Kidney Int 51:1950–1955, 1997ologous regulation of parathyroid hormone receptors in the rat
57. Crowell JA, Cooper CW, Toverud SU, Boass A: Influence ofosteosarcoma cell line UMR-106. Endocrinology 126:2650–2660,
vitamin D on parathyroid hormone-induced adenosine 39,59-mono-1990
phosphate production by bone cells isolated from rat calvariae.39. Abou-Samra A, Zajac J, Schiffer-Alberts D, Skurat R, Kearns
Endocrinology 109:1715–1722, 1981A, Segre G, Bringhurst F: Cyclic adenosine 39,59-monophosphate
58. Shapiro S, Tatakis DN, Dziak R: Effects of tumor necrosis factor(cAMP)-dependent and cAMP-independent regulation of parathy-
alpha on parathyroid hormone-induced increases in osteoblasticroid hormone receptors on UMR106-01 osteoblastic osteosarcoma
cell cyclic AMP. Calcif Tissue Int 46:60–62, 1990cells. Endocrinology 129:2547–2554, 1991
59. Schneider H, Allan E, Moseley J, Martin T, Findlay D: Specific40. Ikeda K, Imai Y, Fukase M, Fujita T: The Effect of 1,25-dihydrox-
down-regulation of parathyroid hormone (PTH) receptors andyvitamin D on human osteoblast-like osteosarcoma cell: Modifica-
responses to PTH by tumour necrosis factor alpha and retinoiction of response to PTH. Biochem Biophys Res Commun 168:889–
acid in UMR 106-06 osteoblast-like osteosarcoma cells. Biochem897, 1990
J 280:451–457, 199141. Bergwitz C, Abou-Samra A, Hesch R, Juppner H: Rapid desensi-
tization of parathyroid hormone dependent adenylate cyclase in 60. Blind E, Knappe V, Raue F, Pfeilschifter J, Ziegler R: TNF
Picton et al: PTH1R mRNA regulation in uremia 1449
inhibits PTH stimulatory effect on cAMP accumulation in SaOS- (PTH)/PTH-related protein (PTHrP) receptor and its messenger
ribonucleic acid in rat aortic vascular smooth muscle cells and2 cell line. Biochem Biophys Res Commun 182:341–347, 1992
UMR osteoblast-like cells: Cell-specific regulation by angiotensin-61. Hanevold CD, Yamaguchi DT, Jordan SC: Tumour necrosis
II and PTHrP. Endocrinology 135:1093–1099, 1994factor alpha modulating parathyroid hormone action in UMR 106-
69. Celic S, Chilco PJ, Zajac JD, Martin TJ, Findlay DM: A type01 osteoblastic cells. J Bone Miner Res 8:1191–1200, 1993
I collagen substrate increases PTH/PTHrP receptor expression and62. Katz MS, Gutierrez GE, Mundy GR, Hymer TK, Caulfield
suppresses PTHrP mRNA expression in UMR 106-06 osteoblast-MP, McKee RL: Tumour necrosis factor and interleukin I inhibit
like cells. J Endocrinol 150:299–308, 1996parathyroid hormone responsive adenylate cyclase in clonal osteo-
70. Hausmann S, Law F, Bonjour J, Feyen J, Rizzoli R: Regulationblast like cells by down regulating parathyroid hormone receptors.
of parathyroid hormone/parathyroid hormone-related protein re-J Cell Physiol 153:206–213, 1992
ceptor expression by osteoblast-deposited extracellular matrix in63. Gutierrez G, Mundy G, Manning D, Hewlett E, Katz M: Trans-
a human osteoblast-like cell line. J Cell Physiol 165:164–171, 1996forming growth factor b enhances parathyroid hormone stimula-
71. Anderson RE, Jee WSS, Woodbury DM: Stimulation of carboniction of adenylate cyclase in clonal osteoblast-like cells. J Cell Phys-
anhydrase in osteoclasts by parathyroid hormone. Calcif Tissueiol 144:438–447, 1990
Int 37:646–650, 198564. Schneider H, Michelangeli V, Frampton R, Grogan J, Ikeda K,
72. Datta HK, Rathod H, Manning P, Turbull Y, McNeil CJ:Martin T, Findlay D: Transforming growth factor-beta modulates
Parathyroid hormone induces superoxide anion burst in the osteo-receptor binding of calciotropic hormones and G protein-mediated
clast: Evidence for the direct instantaneous activation of the osteo-adenylate cyclase responses in osteoblast-like cells. Endocrinology
clast by the hormone. J Endocrinol 149:269–275, 1996131:1383–1389, 1992
73. Hunter SJ, Schraer H, Gay CV: Characterisation of isolated and65. McCauley L, Koh A, Beecher C, Cui Y, Decker J, Franceschi
cultured chick osteoclasts: The effects of acetazolamide, calcitoninR: Effects of differentiation and transforming growth factor. and parathyroid hormone on acid production. J Bone Miner Res
66. Jongen J, Willemstein-Van Hove E, Van Der Meer J, Bos M, 3:297–303, 1988
Juppner H, Segre G, Abou-Samra A, Feyen J, Herrmann-Erlee 74. Hoyland JA, Freemont AJ, Sharpe P: Interleukin 6, IL-6 receptor
M: Down regulation of the receptor for parathyroid hormone and IL-6 nuclear factor gene expression in Paget’s disease. J Bone
(PTH) and PTH-related peptide by transforming growth factor-b Miner Res 9:75–80, 1994
in primary fetal rat osteoblasts. Endocrinology 136:3260–3266, 1995 75. Hoyland JA, Sharpe P: Upregulation of c-fos proto-oncogene
67. Gutierrez GE, Mundy GR, Derynck R, Hewlett EL, Katz MS: expression in Pagetic osteoclasts. J Bone Miner Res 9:1191–1194,
Inhibition of parathyroid hormone-responsive adenylate cyclase 1994
in clonal osteoblast-like cells by transforming growth factor a and 76. Mee AP, Hoyland JA, Braidman IP, Freemont AJ, Davies M,
epidermal growth factor. J Biol Chem 262:15845–15850, 1987 Mawer EB: Demonstration of vitamin D receptor transcripts in
68. Okano K, Wu S, Huang X, Pirola C, Juppner H, Abou-Samra actively resorbing osteoclasts in bone sections. Bone 18:295–299,
1996A, Segre G, Iwasaki K, Fagin J, Clemens T: Parathyroid hormone
